NOV 18, 2019 8:37 PM PST

FDA Approves New Drug for Sickle Cell Disease

WRITTEN BY: Annie Lennon

Sickle cell disease affects approximately 100,000 Americans. Currently, the only available cure for the disease is a costly bone marrow transplant, putting it out of reach of most, with other ways of managing the disease limited to preventative care. Now however, how these symptoms are managed may change with the FDA approval of the first ever targeted therapy for Sickle Cell Disease, Adakveo, developed by pharmaceutical company, Novartis. 

Normally, red blood cells are disk-like in shape. However, due to a genetic mutation for those with Sickle Cell Disease, their red blood cells resemble C-shaped crescents of “sickles”. Due to their shape, they often get stuck to the walls of blood vessels where they cause blockages. This may then result in vaso-occlusive crises in which blood flow to certain parts of the body is blocked (Lee: 2019). 

Leading to severe pain and potential organ damage due to deprivation of oxygen, until now, the only way to manage such crises has been to avoid certain triggers, such as high elevation, extreme cold, physical exhaustion and certain drugs such as acetazolamide. 

Now however, with Adakveo, also known as crizanlizumab-tmca, people with the disease may have another option. For those affected, a protein known as P-selectin found on the cellular lining inside blood vessel walls and platelets enables crescent-shaped red blood cells to stick to blood vessel walls, thus causing blockages. Adakveo works against ths by binding to and blocking P-selectin, thus preventing blockages and preventing vaso-occlusive crises (ibid.). 

The drug’s approval comes following results from a randomized clinical trial of 198 participants. There, researchers showed those who received Adakveo required an average of 1.63 hospital visits per year, whereas those on a placebo required an average of 2.98. The trial also found that those taking the drug had a longer time until experiencing their first vaso-occlusive crisis, and that 36% of those on the drug didn’t have a vaso-occlusive crisis at all throughout the study’s duration (FDA: 2019). 

According to Kenneth I. Attaga MD, director of the Center for Sickle Cell Disease at the University of Tennessee Health Science Center at Memphis, “We know this drug can decrease the frequency of sickle cell pain crisis in a significant and clinically meaningful way...The approval of crizanlizumab is an important advancement for people living with this very difficult condition (Kunzmann: 2019).”

 

Sources

 

Lee, Bruce: Forbes

FDA News

Kunzmann, Kevin: MDmag

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
SEP 13, 2020
Drug Discovery & Development
Scientists Find Way to Reduce Inflammation from Vaccines
SEP 13, 2020
Scientists Find Way to Reduce Inflammation from Vaccines
Researchers from the University of Chicago have found a new way to reduce vaccine-related inflammation from adjuvants, a ...
SEP 11, 2020
Drug Discovery & Development
Novel Therapeutic for ALS
SEP 11, 2020
Novel Therapeutic for ALS
The TDP-43 protein is a well-known hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). A ...
SEP 15, 2020
Drug Discovery & Development
How Can Genetic Data Make Informed Decisions About Drug Development?
SEP 15, 2020
How Can Genetic Data Make Informed Decisions About Drug Development?
How Can Genetic Data Make Informed Decisions About Drug Development? Scientists at the Integrative Epidemiology Unit (MR ...
OCT 22, 2020
Neuroscience
Placebos Impact Brain Patterns for Emotional Processing
OCT 22, 2020
Placebos Impact Brain Patterns for Emotional Processing
Researchers from Michigan State University have found that placebos reduce markers of emotional distress- even when the ...
OCT 29, 2020
Drug Discovery & Development
Scientists Create Antibiotic from Komodo Dragon Blood
OCT 29, 2020
Scientists Create Antibiotic from Komodo Dragon Blood
Researchers from George Mason University in Washington DC have created a synthetic molecule from Komodo Dragon blood tha ...
NOV 02, 2020
Immunology
New Cancer Drug Reboots Stalled Immunotherapies
NOV 02, 2020
New Cancer Drug Reboots Stalled Immunotherapies
In contrast to traditional chemotherapies, immunotherapies reprogram the patient’s own immune system to fight tumo ...
Loading Comments...